Publikationer av Elisa Pin
Refereegranskade
Artiklar
[1]
J. Olofsson et al., "Array-Based Multiplex and High-Throughput Serology Assays," Methods in Molecular Biology, vol. 2628, s. 535-553, 2023.
[2]
M. Geroldinger-Simic et al., "Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis," International Journal of Molecular Sciences, vol. 24, no. 6, 2023.
[3]
F. Mescia et al., "Autoantibody Profiling and Anti-Kinesin Reactivity in ANCA-Associated Vasculitis," International Journal of Molecular Sciences, vol. 24, no. 20, 2023.
[4]
M. Fuentes et al., "Exploring High-Throughput Immunoassays for Biomarker Validation in Rheumatic Diseases in the Context of the Human Proteome Project," Journal of Proteome Research, vol. 22, no. 4, s. 1105-1115, 2023.
[5]
M. Ghorbani et al., "Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV," Frontiers in Immunology, vol. 13, 2023.
[6]
M. Frodlund et al., "The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. : A Swedish nationwide study (COVID19-REUMA)," Vaccine, vol. 41, no. 20, s. 3247-3257, 2023.
[7]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, s. 46-52, 2022.
[8]
K. Asplund Högelin et al., "B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients," European Journal of Neurology, vol. 29, no. 11, s. 3317-3328, 2022.
[9]
L. Blixt et al., "Covid-19 in patients with chronic lymphocytic leukemia : clinical outcome and B- and T-cell immunity during 13 months in consecutive patients," Leukemia, vol. 36, no. 2, s. 476-481, 2022.
[10]
P. Juanes-Velasco et al., "Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid," Cancers, vol. 14, no. 2, 2022.
[11]
L. Blixt et al., "Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination," Blood, vol. 140, no. 22, s. 2403-2407, 2022.
[12]
R. Carapito et al., "Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort," Science Translational Medicine, vol. 14, no. 628, 2022.
[13]
I. Lauren et al., "Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology," Immunity, Inflammation and Disease, vol. 10, no. 4, 2022.
[14]
S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, s. 72-80, 2022.
[15]
S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, s. e0262169-e0262169, 2022.
[16]
K. Healy et al., "Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals," MED, vol. 3, no. 2, s. 137-153, 2022.
[17]
J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.
[18]
S. Havervall et al., "Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2," EBioMedicine, vol. 70, 2021.
[19]
K. A. Högelin et al., "Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis," iScience, vol. 24, no. 9, 2021.
[20]
K. M. Elfstrom et al., "Differences in risk for SARS-CoV-2 infection among healthcare workers," Preventive Medicine Reports, vol. 24, 2021.
[21]
N. Kharlamova et al., "False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases," Frontiers in Immunology, vol. 12, 2021.
[22]
C. Lindblad et al., "Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in blood-brain barrier disruption and outcome prediction following severe traumatic brain injury : a prospective, observational study," Critical Care, vol. 25, no. 1, 2021.
[23]
E. Pin et al., "Immunoglobulin A Autoreactivity toward Brain Enriched and Apoptosis-Regulating Proteins in Saliva of Athletes after Acute Concussion and Subconcussive Impacts," Journal of Neurotrauma, vol. 38, no. 17, s. 2373-2383, 2021.
[24]
G. Cini et al., "Lynch syndrome and Muir-Torre phenotype associated with a recurrent variant in the 3 ' UTR of the MSH6 gene," Cancer Genetics, vol. 254, s. 1-10, 2021.
[25]
P. San Segundo-Acosta et al., "Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers," Journal of Proteome Research, vol. 20, no. 11, s. 5115-5130, 2021.
[26]
H. Alkharaan et al., "Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19 : A Complementary Approach to Population Surveys," Journal of Infectious Diseases, vol. 224, no. 3, s. 407-414, 2021.
[27]
S. Hassan et al., "SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden," Journal of Internal Medicine, vol. 290, no. 2, s. 430-436, 2021.
[28]
S. Hober et al., "Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay," Clinical & Translational Immunology (CTI), vol. 10, no. 7, 2021.
[29]
A. Notarnicola et al., "Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features," Arthritis & Rheumatology, vol. 71, 2019.
[30]
E. Lorenzen et al., "Multiplexed analysis of the secretin-like GPCR-RAMP interactome," Science Advances, vol. 5, no. 9, 2019.
[31]
E. Pin et al., "Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer," Journal of Proteome Research, vol. 16, no. 1, s. 204-216, 2017.
[32]
C. Fredolini et al., "Immunocapture strategies in translational proteomics," Expert Review of Proteomics, vol. 13, no. 1, s. 83-98, 2016.
Kapitel i böcker
[33]
E. Pin et al., "Array-based profiling of proteins and autoantibody repertoires in CSF," i Cerebrospinal Fluid (CSF) Proteomics, : Humana Press Inc., 2019, s. 303-318.
Icke refereegranskade
Artiklar
[34]
M. Frodlund et al., "The impact of immunomodulating treatment on the serological immunogenicity following three doses of covid-19 vaccine and persistence of immunogenicity of two vaccine doses in patients with inflammatory rheumatic diseases - a swedish study (covid19-reuma)," Annals of the Rheumatic Diseases, vol. 82, s. 533-533, 2023.
[35]
M. Frodlund et al., "Predictors Of Antibody Response To Covid-19 Vaccine In Rituximab Treated Patients With Inflammatory Rheumatic Diseases. A Swedish Nationwide Study (Covid19-Reuma)," Annals of the Rheumatic Diseases, vol. 81, s. 368-369, 2022.
[36]
L. Lourido et al., "Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis," Arthritis & Rheumatology, vol. 73, s. 60-62, 2021.
[37]
K. A. Hogelin et al., "Impact of B-cell depleting treatments on development of humoral and cellular immunological memory against SARS-CoV-2," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, s. 348-348, 2021.
[38]
L. Lourido et al., "PRESENCE OF FOUR SERUM AUTOANTIBODIES ASSOCIATES WITH THE ACPA STATUS IN EARLY RHEUMATOID ARTHRITIS," Annals of the Rheumatic Diseases, vol. 80, s. 425-426, 2021.
[39]
Övriga
[40]
A. Jernbom Falk et al., "Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19," (Manuskript).
Senaste synkning med DiVA:
2024-04-30 00:30:21